Especialitat
Retina i Vitri
Títol complet
An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME)
Promotor
Bayer.
Data d'inici
Novembre 2016
Data de finalització
Novembre 2019
Investigadors
Principal: Dra. Anniken Burés.
